Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization
Biochemia medica · 15.06.2026 · 36 (2) · 354-360
DOI: 10.11613/bm.2026.020901 ↗Kurz gefasst
Fallbericht in der Zeitschrift Biochemia medica, online erschienen am 15.06.2026. Verfasst von Iva Ivanko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia. Hauptthemen laut MEDLINE: Tumor Lysis Syndrome, Lymphoma, B-Cell, Bone Marrow. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Tumour lysis syndrome (TLS) is an oncologic emergency usually arising after chemotherapy administration, caused by a massive tumour breakdown and characterized by a specific laboratory and clinical findings. We present a case of TLS, both spontaneous and treatment related, in a 59-year-old woman with high grade B-cell lymphoma without apparent bulky disease on radiologic scans. The patient presented with acute kidney failure with marked hyperuricemia (2764 µmol/L) and extremely high lactate dehydrogenase (LD) activity (13,770 U/L). She was treated with rasburicase, corticosteroid pre-phase therapy, sequential chemotherapy and renal replacement therapy tailored to electrolytic disturbances. After initial resolution of spontaneous TLS, at the start of chemotherapy administration, she experienced systemic inflammatory response (SIRS) and therapy related TLS which included, amongst else, vast hyperphosphatemia (6.12 mmol/L). Despite all intensive care treatment, patient went into multiorgan failure preceding lethal outcome. This case report confirms the value of laboratory parameters in establishing the diagnosis of TLS with LD as an indicator of massive tumour turnover. Due to a high risk of deleterious complications, management of extreme TLS cases challenges the current guidelines of TLS therapy. Modern treatment options such as targeted anticytokine therapy could potentially bring benefit in these specific circumstances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia.
- School of Medicine, Catholic University of Croatia, Zagreb, Croatia.
- Department of Nephrology and Arterial Hypertension, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia.
- Department of Clinical Chemistry, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia.
- Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
- Department of Pathology and Cytology, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia.
Zitieren
APA
Ivanko, I., Josipović, J., Ćelap, I., Novaković Coha, S., Matijaca, H., Brblić, T., Kojić Katović, S., & Gaćina, P. (2026). Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization. Biochemia medica, 36(2), 354-360. https://doi.org/10.11613/bm.2026.020901
Vancouver
Ivanko I, Josipović J, Ćelap I, Novaković Coha S, Matijaca H, Brblić T, et al. Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization. Biochemia medica. 2026;36(2):354-360. doi:10.11613/bm.2026.020901
BibTeX
@article{Ivanko2026,
author = {Ivanko, Iva and Josipović, Josipa and Ćelap, Ivana and Novaković Coha, Sabina and Matijaca, Hana and Brblić, Tomislav and Kojić Katović, Sandra and Gaćina, Petar},
title = {Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization},
journal = {Biochemia medica},
year = {2026},
volume = {36},
number = {2},
pages = {354--360},
doi = {10.11613/bm.2026.020901}
}
EUVIMED